Allogeneic hematopoietic cell transplantation for multiple myeloma

https://doi.org/10.1016/S0037-1963(01)90016-2Get rights and content

Abstract

Some patients with multiple myeloma (MM) who have undergone allogeneic hematopoietic stem cell transplants remain free of disease 5 to 13 years later—a major accomplishment for a malignancy that had been resistant to all investigational therapies. Although it will require longer follow-up to determine how many are truly cured, results for patients with MM transplanted from identical twins suggest that long-term progression-free survival is possible. While 3- to 5-year survival is similar after allogeneic or autologous stem cell transplant for MM, only allograft recipients appear to enjoy long-term disease-free survival, most likely due to an allogeneic graft-versus-myeloma (GVM) effect. The very high transplant-related mortality associated with standard allogeneic stem cell transplantation is currently the major limitation to wider use of this potentially curative treatment. The challenge for clinical investigators will be to reduce the incidence of posttransplant complications. Strategies include the use of nonablative conditioning for allografts, the administration of peripheral blood stem cells (PBSC) rather than bone marrow, and the application of more focused, targeted conditioning therapies such as bone-seeking radioisotopes.

References (45)

  • R Storb et al.

    Mixed hematopoietic chimerism after hematopoietic stem cell allografts

    Transplant Proc

    (1999)
  • G Tricot et al.

    Graft-versusmyeloma effect: Proof of principle

    Blood

    (1996)
  • LF Verdonck et al.

    Graft-versus-myeloma effect in two cases

    Lancet

    (1996)
  • E Alyea et al.

    Induction of graft versus myeloma by donor lymphocyte infusions following allogeneic bone marrow transplant

  • OF Ballester

    Allogeneic bone marrow transplantation for multiple myeloma

  • JE Bayouth et al.

    Pharmacokinetics, dosimetry and toxicity of holmium-166-DOTMP for bone marrow ablation in multiple myeloma

    J Nucl Med

    (1995)
  • W Bensinger et al.

    Phase I–II study of 166holmium-DOTMP in combination with melphalan +/—total body irradiation (TBI) with autologous peripheral blood stem cell transplant (PBSCT) for patients with multiple myeloma (MM)

  • WI Bensinger et al.

    Syngeneic marrow transplantation in patients with multiple myeloma

    Bone Marrow Transplant

    (1996)
  • WI Bensinger et al.

    Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers

    N Engl J Med

    (2001)
  • H Bertz et al.

    Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): Evidence for a graftversus-myeloma effect

    Leukemia

    (1997)
  • JM Bird et al.

    Minimal residual disease after bone marrow transplantation for multiple myeloma: Evidence for cure in long-term survivors

    Bone Marrow Transplant

    (1993)
  • M Cavo et al.

    Allogeneic stem cell transplants for multiple myeloma. Bologna experience

  • Cited by (42)

    • Graft-Versus-Host Disease in Multiple Myeloma Patients Treated With Daratumumab After Allogeneic Transplantation

      2020, Clinical Lymphoma, Myeloma and Leukemia
      Citation Excerpt :

      These include daratumumab, an anti-CD38 antibody, and elotuzumab, an anti-SLAMF7 antibody.2 Patients can be considered for allogeneic hematopoietic cell transplantation (allo-HCT) as a curative-intent option for high-risk disease or as an upfront therapy (as tandem autologous/allo-HCT approach) for relapsed MM after failure of one or more lines of therapy, including ASCT.3-8 Most recently, consolidation with allo-HCT (tandem) after ASCT has shown favorable long-term outcomes in a postrelapse setting of patients with MM.9

    • SOHO State of the Art Updates and Next Questions: T-Cell–Directed Immune Therapies for Multiple Myeloma: Chimeric Antigen Receptor–Modified T Cells and Bispecific T-Cell–Engaging Agents

      2019, Clinical Lymphoma, Myeloma and Leukemia
      Citation Excerpt :

      There is a strong rationale to investigate immunotherapeutic approaches for MM. Durable complete remissions (CRs) in MM were reported with allogeneic stem-cell transplantation (allo-SCT), and in some cases, relapses after allo-SCT were rescued by donor lymphocyte infusion.3-6 These results demonstrated that immunologic therapy in the form of a graft-versus-tumor effect, mediated primarily by T cells, was capable of conferring long-term control of this disease.

    • Role of Allogeneic Stem Cell Transplantation in Multiple Myeloma

      2009, Seminars in Hematology
      Citation Excerpt :

      Moreover, further evidence for graft-versus-myeloma effects are the molecular remissions, prelude to possible cure, that are more commonly observed after myeloablative allografting as compared to autografting and that can occur in up to 50% of patients.27 The most frequently used myeloablative conditionings have included cyclophosphamide with total body irradiation or busulfan, or melphalan and total body irradiation.12-14,28,29 The unacceptably high treatment-related mortality of up to 60% has commonly restricted this approach to young, usually in their fifth decade, medically fit patients.12-14

    View all citing articles on Scopus

    Supported in part by Grants No. CA-18029, CA-78902, CA-47748, CA-18221, CA-15704, CA-58576, CA-09319, and CA-09515 from the National Cancer Institute, and HL 36444 from the National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD; the Jose Carreras Foundation Against Leukemia, Barcelona, Spain; and the Joseph Steiner Krebstifftung, Bern, Switzerland.

    View full text